Abstract:
The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 2. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
Abstract translation:本发明涉及病原菌的新型药物靶标。 因此,本发明提供了包含SEQ ID NO:2所示的氨基酸序列的纯化蛋白质。本发明还提供本发明多肽的生物化学和生物物理学特征。
Abstract:
In part, the present invention is directed to compositions having a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions having a compound of formulas I-III and at least one other antibacterial agent.
Abstract:
In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.
Abstract:
The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein derived from Fransicella tularensis comprising the amino acid sequence set forth in SEQ ID NO: 2. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
Abstract translation:本发明涉及病原菌的新型药物靶标。 因此,本发明提供了从包含SEQ ID NO:2所示氨基酸序列的土拉氏弗斯兰氏菌得到的纯化蛋白质。本发明还提供了本发明多肽的生物化学和生物物理学特征。
Abstract:
In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or functionally, for example, Fab K. Kits and compositions that include the disclosed compounds are also provided. Methods of treating a subject with a bacterial illness is also disclosed.
Abstract:
In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.